News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
262,851 Results
Type
Article (14021)
Company Profile (304)
Press Release (248526)
Section
Business (79403)
Career Advice (152)
Deals (13207)
Drug Delivery (34)
Drug Development (50370)
Employer Resources (31)
FDA (5691)
Job Trends (5120)
News (144217)
Policy (10019)
Tag
Academia (901)
Alliances (21576)
Alzheimer's disease (781)
Antibody-drug conjugate (ADC) (64)
Approvals (5679)
Artificial intelligence (80)
Bankruptcy (99)
Best Places to Work (4539)
Biotechnology (249)
Breast cancer (121)
Cancer (998)
Cardiovascular disease (83)
Career advice (132)
CAR-T (82)
Cell therapy (240)
Clinical research (40330)
Collaboration (373)
Compensation (152)
COVID-19 (1013)
C-suite (99)
Cystic fibrosis (71)
Data (1047)
Diabetes (92)
Diagnostics (1215)
Earnings (29048)
Events (47381)
Executive appointments (297)
FDA (6116)
Funding (359)
Gene editing (70)
Gene therapy (179)
GLP-1 (326)
Government (1065)
Healthcare (6559)
Infectious disease (1054)
Inflammatory bowel disease (100)
IPO (7218)
Job creations (859)
Job search strategy (127)
Layoffs (191)
Legal (1377)
Lung cancer (146)
Lymphoma (63)
Manufacturing (91)
Medical device (2563)
Medtech (2564)
Mergers & acquisitions (6170)
Metabolic disorders (283)
Neuroscience (1060)
NextGen: Class of 2025 (2013)
Non-profit (850)
Northern California (1197)
Obesity (154)
Opinion (94)
Parkinson's disease (82)
Patents (68)
People (25214)
Phase I (14229)
Phase II (18748)
Phase III (11873)
Pipeline (447)
Postmarket research (851)
Preclinical (5979)
Radiopharmaceuticals (207)
Rare diseases (221)
Real estate (1411)
Regulatory (8349)
Research institute (932)
Series A (71)
Southern California (1075)
Startups (1967)
United States (9478)
Vaccines (174)
Weight loss (91)
Date
Today (35)
Last 7 days (208)
Last 30 days (1128)
Last 365 days (20389)
2025 (991)
2024 (20577)
2023 (22415)
2022 (26824)
2021 (27806)
2020 (23357)
2019 (16225)
2018 (11738)
2017 (13745)
2016 (11840)
2015 (14351)
2014 (10394)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (17018)
Australia (2871)
California (2725)
Canada (867)
China (247)
Colorado (101)
Connecticut (116)
Europe (36601)
Florida (303)
Georgia (78)
Illinois (169)
Indiana (66)
Maryland (362)
Massachusetts (2166)
Minnesota (111)
New Jersey (672)
New York (749)
North Carolina (442)
Northern California (1197)
Ohio (87)
Pennsylvania (523)
South America (207)
Southern California (1075)
Texas (304)
Washington State (266)
262,851 Results for "taurx therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
TauRx Submits UK Marketing Authorisation Application for HMTM as a Treatment for Alzheimer’s Disease
TauRx Pharmaceuticals Ltd has announced the submission of a UK Marketing Authorisation Application for hydromethylthionine mesylate for treatment of mild cognitive impairment and mild to moderate stages of dementia due to Alzheimer’s disease.
July 1, 2024
·
3 min read
Drug Development
Two Year Sustained Cognitive Benefits of Hydromethylthionine Mesylate (HMTM) Indicated by TauRx’s LUCIDITY Trial
TauRx Pharmaceuticals Ltd., a global leader in tau-based research in Alzheimer’s disease (AD), presented the 24-month data from its Phase 3 LUCIDITY trial of hydromethylthionine mesylate (HMTM) at the AD/PD™ 2024 Alzheimer’s & Parkinson’s Diseases Conference in Lisbon, Portugal.
March 7, 2024
·
6 min read
Drug Development
TauRx to Present Two-Year Data from Phase III Trial of HMTM in Alzheimer’s Disease at the AD/PD™ 2024 Conference in March
TauRx Pharmaceuticals Ltd. announced that the company will present the 24-month data from its Phase III LUCIDITY trial of hydromethylthionine mesylate at the upcoming AD/PD™ 2024 Alzheimer’s & Parkinson’s Diseases Conference from 5-9 March 2024, in Lisbon, Portugal.
February 5, 2024
·
4 min read
Drug Development
TauRx’s Hydromethylthionine Mesylate (HMTM) Demonstrates Significant Reduction in Neurodegeneration in Alzheimer’s Disease (AD)
TauRx Pharmaceuticals Ltd. announced results from a prespecified analysis of the Phase 3 LUCIDITY trial that measured the impact of HMTM on neurofilament light chain, an established biomarker for brain neurodegeneration.
July 16, 2023
·
4 min read
Drug Development
CTAD: TauRx Touts Safety Profile as Anavex Stumbles over Data Discrepency (Updated)
TauRx Pharmaceuticals and Anavex Life Sciences presented positive results from their candidates at the Clinical Trials in Alzheimer’s Disease (CTAD) conference in San Francisco, CA.
December 2, 2022
·
3 min read
·
Kate Goodwin
Drug Development
TauRx Announces Results from Phase 3 Alzheimer’s Disease Study, LUCIDITY, Assuring Path for Regulatory Submissions
TauRx Pharmaceuticals Ltd is a global leader in tau-based research in Alzheimer’s disease.
October 6, 2022
·
8 min read
Drug Development
TauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results
TauRx Pharmaceuticals Ltd is a global leader in tau-based research in Alzheimer’s disease. Pathological aggregation of Tau correlates with clinical disease severity and brain atrophy.
November 14, 2022
·
3 min read
Drug Development
TauRx Deems Phase III Data Sufficient to Send Tau Inhibitor to Regulators
TauRx announced preliminary results from the Phase III study, showing HMTM, its potent inhibitor of tau aggregates, could slow Alzheimer’s disease progression or cognitive decline.
October 6, 2022
·
3 min read
·
Tristan Manalac
Drug Development
TauRx’s late-stage clinical trial reaches new milestone
TauRx Pharmaceuticals Ltd, a global leader in tau-based Alzheimer’s Disease research, has announced that the last patient has completed treatment in the blinded phase of their late-stage clinical trial, Lucidity.
April 14, 2022
·
2 min read
Drug Development
Tau-targeting Alzheimer’s treatment, HMTM, moving toward regulatory submission based on initial data from TauRx’s LUCIDITY trial
TauRx Pharmaceuticals Ltd, the global leader in tau-based research in Alzheimer’s, announced unblinding of initial data from completion of the randomised portion of their pivotal Phase 3 clinical trial, LUCIDITY.
June 1, 2022
·
4 min read
1 of 26,286
Next
